Project Grant HT94252510246
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$924K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The Defense Health Agency awarded a $533,308 project grant to the Sloan-Kettering Institute for Cancer Research in New York, NY under the Military Medical Research and Development (CFDA 12.420) program. The grant, which runs from September 1, 2025 to August 31, 2029, will support integrated immunomodulatory analysis of LAG3 inhibition in renal cell carcinoma. The Sloan-Kettering Institute, a leading nonprofit cancer research institution, will conduct advanced biomedical research aimed at...
The Defense Health Agency awarded a $1,108,654 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 30, 2025, will fund research to accelerate global research for relapsed or refractory extracranial malignant germ cell tumors. The Sloan-Kettering Institute, a leading nonprofit cancer research institution, will leverage its extensive capabilities in cancer biology, genomics,...
The Defense Health Agency has awarded a $1,387,727 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma", will fund research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative approaches to cancer diagnosis,...
The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...
The Sloan-Kettering Institute for Cancer Research was awarded a $707,346 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2024, supports Sloan-Kettering's cancer research initiatives, including investigations into the tumor microenvironment, mechanisms of metastasis, epigenetic alterations in cancer, resistance to cancer therapies, aging-related biology, and hematologic malignancies....
The Defense Health Agency awarded a $924,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant, titled "Therapeutic Strategies for Targeting Diverse KRAS Mutations in Lung Cancer," will fund advanced cancer research focused on developing innovative treatments for lung cancer. The research aims to investigate therapeutic approaches for targeting diverse KRAS mutations, a...
Sloan-Kettering Institute For Cancer Research was awarded a $845,789 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 1, 2023 to June 30, 2026. The grant will support research to discover biomarkers and address outcome disparities for prostate cancer through exploiting real-world clinical genomic data. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise...
The Defense Health Agency awarded a $3,705,142 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant supports a Phase 2 study of sacituzumab govitecan-hziyin in patients with previously treated mesotheliomas. The research aims to transform healthcare for military service members, veterans, and the broader public through innovative and impactful medical research. The study will be conducted at the...
The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...